EN
登录

AI药物开发商Isomorphic Labs宣布获得6亿美元融资,用于进一步开发其下一代人工智能药物设计引擎,并推动治疗项目进入临床阶段

Isomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic

CISION 等信源发布 2025-03-31 19:27

可切换为仅中文


Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline.

Isomorphic Labs 将利用这笔资金通过前沿的人工智能研究与开发进一步推动其 AI 药物设计引擎,并扩大和推进其候选药物管道。

LONDON

伦敦

,

,

March 31, 2025

2025年3月31日

/PRNewswire/ -- Isomorphic Labs, an AI-first drug design and development company, today announced it has raised

/PRNewswire/ -- Isomorphic Labs,一家以人工智能为先导的药物设计与开发公司,今天宣布已完成融资

$600 Million

6亿美元

in its first external funding round. The financing round is led by Thrive Capital, with participation from GV, and follow-on capital from existing investor, Alphabet.

在其第一轮外部融资中。本轮融资由Thrive Capital领投,GV参与,现有投资者Alphabet继续追加投资。

Isomorphic Labs was founded with the ambition to leverage the power of AI to reimagine and accelerate drug discovery to bring much-needed treatments to millions of patients globally. The company aims to apply its pioneering AI drug design engine to deliver biomedical breakthroughs and is advancing drug design programs across multiple therapeutic areas and drug modalities. .

Isomorphic Labs 的创立初衷是利用人工智能的力量,重新构想并加速药物发现过程,为全球数百万患者带来亟需的治疗方案。该公司旨在应用其开创性的 AI 药物设计引擎来实现生物医学突破,并正在多个治疗领域和药物模式上推进药物设计项目。

'We're excited to bring together a top-tier investor group with deep AI and life sciences expertise as we aim to transform this industry through an interdisciplinary approach,' said Isomorphic Labs founder and CEO, Sir Demis Hassabis. 'This funding will further turbocharge the development of our next-generation AI drug design engine, help us advance our own programs into clinical development, and is a significant step forward towards our mission of one day solving all disease with the help of AI.' .

“我们很高兴能够汇集一群具有深厚人工智能和生命科学专业知识的顶级投资者,因为我们希望通过跨学科的方法来变革这个行业,”Isomorphic Labs创始人兼首席执行官Demis Hassabis爵士表示。“这笔资金将进一步加速我们下一代人工智能药物设计引擎的开发,帮助我们推进自己的项目进入临床开发阶段,并且是我们朝着有朝一日借助人工智能解决所有疾病这一使命迈出的重要一步。”

Since its founding, the company has developed a number of next-generation AI models that come together to form its unified AI drug design engine that works across multiple therapeutic areas and drug modalities. One example breakthrough model is AlphaFold 3, developed and released in

自成立以来,该公司开发了多个下一代人工智能模型,这些模型共同构成了其跨多个治疗领域和药物模式的统一AI药物设计引擎。其中一个突破性模型是AlphaFold 3,于开发并发布。

May 2024

2024年5月

by Isomorphic Labs together with Google DeepMind, with the ability to accurately predict the structure and interactions of all of life's molecules. Leveraging these state-of-the-art AI technologies, Isomorphic Labs has established a drug discovery portfolio consisting of partnered programs with pharmaceutical industry leaders Eli Lilly and Novartis, as well as internal programs primarily focused in oncology and immunology.

由Isomorphic Labs与Google DeepMind共同开发,能够准确预测所有生命分子的结构和相互作用。通过利用这些最先进的AI技术,Isomorphic Labs建立了包括与制药业领导者礼来公司和诺华公司合作的项目,以及主要集中在肿瘤学和免疫学领域的内部项目的药物发现组合。

Novartis and Isomorphic Labs recently expanded the scope of their original collaboration just over a year after initiating the relationship. .

诺华和Isomorphic Labs在建立合作关系一年多后,最近扩大了原有合作的范围。

'At Thrive, we aim to invest in category-defining companies with singular conviction, and that has led us to Isomorphic Labs,' said

“在Thrive,我们旨在投资具有独特信念的定义类别的公司,这使得我们选择了Isomorphic Labs,”

Joshua Kushner

乔舒亚·库什纳

, Founder and CEO of Thrive Capital. 'We believe Isomorphic has earned a rare position to define a new age of drug discovery and design, and we are deeply inspired by their mission and the extraordinary progress they have made to date.'

Thriving Capital的创始人兼首席执行官表示:“我们认为,同构公司已经获得了一个定义药物发现和设计新时代的罕见地位,他们的使命以及迄今为止取得的非凡进展深深地激励了我们。”

The investment will accelerate Isomorphic Labs' frontier AI research and development, to rapidly advance the company's next-generation AI drug design engine. Isomorphic Labs will consequently be expanding its team of world-class talent as part of its next phase of growth.

这项投资将加速Isomorphic Labs的前沿人工智能研究与开发,快速推进公司下一代人工智能药物设计引擎的发展。因此,Isomorphic Labs将在其下一阶段的增长中扩大其世界级人才团队。

'AI and machine learning have long held the promise of transforming drug discovery, yet few companies over the past decade have unlocked their full potential. After witnessing the extraordinary pace of innovation at Isomorphic Labs, we believe their pioneering approach will redefine AI-powered drug discovery,' said Dr.

“人工智能和机器学习长期以来一直有望变革药物发现,但在过去的十年中,很少有公司能够充分释放它们的潜力。在目睹了Isomorphic Labs非凡的创新速度后,我们相信他们开创性的方法将重新定义人工智能驱动的药物发现,”博士表示。

.

。

Krishna Yeshwant

克里希纳·耶什万特

, Managing Partner at GV. 'With Sir Demis Hassabis at the helm, Isomorphic has assembled an exceptional team at the intersection of life sciences and technology. We're proud to support them as they advance the development of new treatments for patients.'

GV管理合伙人表示:“在德米斯·哈萨比斯爵士的带领下,Isomorphic汇集了一支生命科学与技术交叉领域的杰出团队。我们很自豪能够支持他们推进患者新疗法的开发。”

ABOUT ISOMORPHIC LABS

关于同构实验室

Isomorphic Labs was founded in 2021, with a mission to transform drug discovery with the power of artificial intelligence, ushering in a new era of biomedical breakthroughs. Isomorphic Labs is led by AI pioneer Sir Demis Hassabis, and its founding was built on the Nobel-winning AI breakthrough, AlphaFold.

Isomorphic Labs 成立于 2021 年,使命是利用人工智能的力量彻底改变药物发现,开启生物医学突破的新时代。Isomorphic Labs 由人工智能先驱 Demis Hassabis 爵士领导,其创立基于荣获诺贝尔奖的人工智能突破性成果 AlphaFold。

Isomorphic Labs, together with Google DeepMind, developed and released .

Isomorphic Labs 与 Google DeepMind 联合开发并发布了 。

AlphaFold 3

阿尔法折叠3

in

在

May 2024

2024年5月

, a revolutionary AI model that can predict the structure and interactions of all of life's molecules with unprecedented accuracy. Isomorphic Labs has built a world-leading AI drug design engine comprising foundational AI models that are capable of working across multiple therapeutic areas and drug modalities.

,这是一款革命性的AI模型,能够以前所未有的准确性预测所有生命分子的结构和相互作用。Isomorphic Labs构建了一个世界领先的AI药物设计引擎,包含基础性AI模型,这些模型能够跨多个治疗领域和药物模式工作。

The company is continually innovating on model architecture and developing cutting-edge capabilities to advance drug design. Isomorphic Labs is headquartered in .

该公司不断在模型架构上创新,并开发尖端能力以推动药物设计。Isomorphic Labs 总部位于。

London

伦敦

and has an office in Lausanne, Switzerland.

并在瑞士洛桑设有办事处。

Isomorphic Labs is advancing a broad and ambitious drug design portfolio through partnered programs and wholly-owned internal programs.

Isomorphic Labs 正在通过合作项目和全资内部项目推进广泛且宏大的药物设计组合。

For more information, go to

欲了解更多信息,请访问

www.isomorphiclabs.com

www.isomorphiclabs.com

and follow us on

关注我们

LinkedIn

领英

and

和

X

X

.

。

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM?

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用